Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR-PD
NCT03815916Phase 2Completed
- Sponsor
- Clene Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CNM-Au8 in Parkinson's disease (PD) (4 arms), sponsored by Clene Inc. Primary endpoint: 31P-MRS Redox Ratio at 12 weeks. Started Dec 2019; status: completed.
02
Drugs
CNM-Au8
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03815916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815916.